Actively Recruiting
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Led by The First Affiliated Hospital of Xiamen University · Updated on 2026-03-09
60
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
CONDITIONS
Official Title
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated neuroendocrine carcinoma supported by imaging findings and pathology report
- Serum ProGRP or NSE level at least three times the upper limit of normal
- Ability to provide informed consent and assent according to ethics guidelines
- Estimated life expectancy of more than 3 months and ability to comply with study procedures and visits
You will not qualify if you...
- Unable or unwilling to provide written informed consent
- Unable to complete PET/CT imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
L
Liang Zhao
CONTACT
H
Haojun Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here